Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer

Cancer Letters

Volumn 382, Issue 1, 2016, Pages 32-43

  Hu, Shi ^a   Dai, Haibin ^b   Li, Tian ^a   Tang, Ying ^a   Fu, Wenyan ^c   Yuan, Qingning ^a   Wang, Feifei ^a   Lv, Gaojian ^a   Lv, Yuanyuan ^a   Fan, Xiaoyan ^a   Zhang, Sheng ^d   Jin, Ruobing ^d   Shen, Yafeng ^a   Lin, Fangxing ^a   Ye, Xuting ^a   Ding, Min ^e   Yang, Yongji ^a   Lei, Changhai ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e Fengchao Medical Technology (Shanghai) Co Ltd   (China)

Author keywords

Acquire resistance; Broad targeted therapy; CRC; Viral vectors

Indexed keywords

58C46; ANTINEOPLASTIC AGENT; AXL PROTEIN; CELL PROTEIN; CETUXIMAB; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR; FICLATUZUMAB; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIZATION; IMMUNOPROPHYLAXIS; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR RECURRENCE; TUMOR REGRESSION; TUMOR RESISTANCE; VECTORED IMMUNOPROPHYLAXIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DEPENDOPARVOVIRUS; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PROCEDURES; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CETUXIMAB; COLORECTAL NEOPLASMS; DEPENDOVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84984813625     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.08.022     Document Type: Article

References (56)

1. [1] Siegel, R., DeSantis, C., Jemal, A., Colorectal cancer statistics. CA Cancer J. Clin 64:2014 (2014), 104–117.
2. [2] Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., Bardelli, A., Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 4 (2014), 1269–1280.
3. [3] McGranahan, N., Swanton, C., Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27 (2015), 15–26.
4. [4] Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., et al. Mutational landscape and significance across 12 major cancer types. Nature 502 (2013), 333–339.
5. [5] Bettegowda, C., Sausen, M., Leary, R.J., Kinde, I., Wang, Y., Agrawal, N., et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci. Transl. Med, 6, 2014 224ra224.
6. [6] Ahronian, L.G., Sennott, E.M., Van Allen, E.M., Wagle, N., Kwak, E.L., Faris, J.E., et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 5 (2015), 358–367.
7. [7] Russo, M., Siravegna, G., Blaszkowsky, L.S., Corti, G., Crisafulli, G., Ahronian, L.G., et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov 6 (2015), 147–153.
8. [8] Hu, S., Fu, W., Xu, W., Yang, Y., Cruz, M., Berezov, S.D., et al. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res 75 (2015), 159–170.
9. [9] Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1 (2011), 508–523.
10. [10] Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med, 3, 2011, 99ra86.
11. [11] Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 3 (2013), 658–673.
12. [12] Balazs, A.B., Chen, J., Hong, C.M., Rao, D.S., Yang, L., Baltimore, D., Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481 (2012), 81–84.
13. [13] Gross, M.E., Zorbas, M.A., Danels, Y.J., Garcia, R., Gallick, G.E., Olive, M., et al. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 51 (1991), 1452–1459.
14. [14] Nissenson, R.A., Diep, D., Strewler, G.J., Synthetic peptides comprising the amino-terminal sequence of a parathyroid hormone-like protein from human malignancies. Binding to parathyroid hormone receptors and activation of adenylate cyclase in bone cells and kidney. J. Biol. Chem 263 (1988), 12866–12871.
15. [15] Deal, C., Balazs, A.B., Espinosa, D.A., Zavala, F., Baltimore, D., Ketner, G., Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 12528–12532.
16. [16] Auricchio, A., Kobinger, G., Anand, V., Hildinger, M., O'Connor, E., Maguire, A.M., et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum. Mol. Genet 10 (2001), 3075–3081.
17. [17] Rohr, U.-P., Wulf, M.-A., Stahn, S., Steidl, U., Haas, R., Kronenwett, R., Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J. Virol. Methods 106 (2002), 81–88.
18. [18] Hudziak, R.M., Ullrich, A., Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum. J. Biol. Chem 266 (1991), 24109–24115.
19. [19] Franklin, M.C., Carey, K.D., Vajdos, F.F., Leahy, D.J., de Vos, A.M., Sliwkowski, M.X., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 (2004), 317–328.
20. [20] Agus, D.B., Akita, R.W., Fox, W.D., Lewis, G.D., Higgins, B., Pisacane, P.I., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2 (2002), 127–137.
21. [21] Muthuswamy, S.K., Gilman, M., Brugge, J.S., Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol. Cell. Biol 19 (1999), 6845–6857.
22. [22] Jhawer, M., Goel, S., Wilson, A.J., Montagna, C., Ling, Y.-H., Byun, D.-S., et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68 (2008), 1953–1961.
23. [23] Swanton, C., Marani, M., Pardo, O., Warne, P.H., Kelly, G., Sahai, E., et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11 (2007), 498–512.
24. [24] Zhang, Z., Wang, J., Ji, D., Wang, C., Liu, R., Wu, Z., et al. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. Clin. Cancer Res 20 (2014), 4559–4573.
25. [25] Hynes, N.E., MacDonald, G., ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol 21 (2009), 177–184.
26. [26] Yarden, Y., Sliwkowski, M.X., Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol 2 (2001), 127–137.
27. [27] Brand, T.M., Iida, M., Wheeler, D.L., Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol. Ther 11 (2011), 777–792.
28. [28] Jonker, D.J., O'Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.-J., et al. Cetuximab for the treatment of colorectal cancer. NEJM 357 (2007), 2040–2048.
29. [29] Vermorken, J.B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. NEJM 359 (2008), 1116–1127.
30. [30] Pirker, R., Pereira, J.R., Szczesna, A., Von Pawel, J., Krzakowski, M., Ramlau, R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373 (2009), 1525–1531.
31. [31] Vaughn, C.P., ZoBell, S.D., Furtado, L.V., Baker, C.L., Samowitz, W.S., Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50 (2011), 307–312.
32. [32] Valtorta, E., Misale, S., Sartore-Bianchi, A., Nagtegaal, I.D., Paraf, F., Lauricella, C., et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int. J. Cancer 133 (2013), 1259–1265.
33. [33] De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11 (2010), 753–762.
34. [34] Karapetis, C.S., Jonker, D., Daneshmand, M., Hanson, J.E., O'Callaghan, C.J., Marginean, C., et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer – results from NCIC CTG/AGITG CO. 17. Clin. Cancer Res 20 (2014), 744–753.
35. [35] Network, C.G.A., Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
36. [36] Saltz, L.B., Meropol, N.J., Loehrer, P.J., Needle, M.N., Kopit, J., Mayer, R.J., Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol 22 (2004), 1201–1208.
37. [37] Diaz, L.A. Jr., Williams, R.T., Wu, J., Kinde, I., Hecht, J.R., Berlin, J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486 (2012), 537–540.
38. [38] Pao, W., Miller, V.A., Politi, K.A., Ricly, G., Somwar, R., Zakowski, M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, 2005 e73.
39. [39] Mohan, S., Heitzer, E., Ulz, P., Lafer, I., Lax, S., Auer, M., et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet, 10, 2014 e1004271.
40. [40] Galizia, G., Lieto, E., Ferraraccio, F., De Vita, F., Castellano, P., Orditura, M., et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann. Surg. Oncol 13 (2006), 823–835.
41. [41] Mendelsohn, J., Baselga, J., Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol 21 (2003), 2787–2799.
42. [42] Riely, G.J., Pao, W., Pham, D., Li, A.R., Rizvi, N., Venkatraman, E.S., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res 12 (2006), 839–844.
43. [43] Schaefer, G., Shao, L., Totpal, K., Akita, R.W., Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res 67 (2007), 1228–1238.
44. [44] Tanizaki, J., Okamoto, I., Sakai, K., Nakagawa, K., Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br. J. Cancer 105 (2011), 807–813.
45. [45] Schaefer, G., Haber, L., Crocker, L.M., Shia, S., Shao, L., Dowbenko, D., et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20 (2011), 472–486.
46. [46] Wheeler, D.L., Huang, S., Kruser, T.J., Nechrebecki, M.M., Armstrong, E.A., Benavente, S., et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27 (2008), 3944–3956.
47. [47] Byers, L.A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., et al. An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies AXL as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res 19 (2013), 279–290.
48. [48] Giles, K.M., Kalinowski, F.C., Candy, P.A., Epis, M.R., Zhang, P.M., Redfern, A.D., et al. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol. Cancer Ther 12 (2013), 2541–2558.
49. [49] Meyer, A.S., Miller, M.A., Gertler, F.B., Lauffenburger, D.A., The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci. Signal, 6, 2013, ra66.
50. [50] Zhang, Z., Lee, J.C., Lin, L., Olivas, V., Au, V., LaFramboise, T., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet 44 (2012), 852–860.
51. [51] Rho, J.K., Choi, Y.J., Kim, S.Y., Kim, T.W., Choi, E.K., Yoon, S.-J., et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res 74 (2014), 253–262.
52. [52] Linger, R.M., Cohen, R.A., Cummings, C.T., Sather, S., Migdall-Wilson, J., Middleton, D.H., et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 32 (2013), 3420–3431.
53. [53] Dunne, P.D., McArt, D.G., Blayney, J.K., Kalimutho, M., Greer, S., Wang, T., et al. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin. Cancer Res 20 (2014), 164–175.
54. [54] Brand, T.M., Iida, M., Stein, A.P., Corrigan, K.L., Braverman, C.M., Luthar, N., et al. AXL mediates resistance to cetuximab therapy. Cancer Res 74 (2014), 5152–5164.
55. [55] Ho, D., Wykoff-Clary, S., Gross, C., Schneider, D., Jin, F., Kretschmer, P., et al. Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer Gene Ther 16 (2009), 184–194.
56. [56] Watanabe, M., Boyer, J.L., Crystal, R.G., AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther 17 (2010), 1042–1051.